Chemomab Therapeutics Bolsa (NASDAQ: CMMB)

Últimas noticias sobre Chemomab Therapeutics (NASDAQ:CMMB) Bolsa

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics Ltd

WIIM

LUXH

LuxUrban Hotels shares are trading lower after the company reported worse-than-expected Q3 financial results.

TD Cowen analyst Jeffrey Osborne maintains Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) with a Hold and raises the price target from $0.25 to $1.25.

News

Price Target

Analyst Ratings

WKHS

TD Cowen Maintains Hold on Workhorse Gr, Raises Price Target to $1.25

EFSH

1847 Holdings shares are trading lower. The company reported Q3 financial results.

On Wednesday, Sage Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)&nbsp;revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42084056/sage-therapeutics-announces-topline-results-from-the-phase-2-dimension-study-of-dalzanemdor-sage-7" rel="noreferrer noopener">Huntington&#8217;s Disease (HD)</a>, an inherited brain disorder that causes nerve cells in the brain to break down and die.
In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce" rel="noreferrer noopener">After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce</a>
SDMT is used for cognitive evaluation, and measures sustained attention, processing speed, visual scanning, and motor speed.&nbsp;
Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo.
Based on these results, the company does not plan to develop dalzanemdor further.
&#8220;We are disappointed by the results of the DIMENSION Study,&#8221; said Barry Greene, Chief Executive Officer of Sage Therapeutics.
Dalzanemdor was generally well-tolerated, and no new safety signals were observed. The majority of treatment-emergent adverse events were mild to moderate in severity.
Given these findings, the company will also close the ongoing PURVIEW Study, an open-label safety study of dalzanemdor in participants with HD.
In October, Sage Therapeutics released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41228587/after-disappointing-parkinsons-data-sage-therapeutics-dalzanemdor-flunks-mid-stage-alzheimers-stu" rel="noreferrer noopener">Alzheimer's Disease (AD)</a>.
The LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, the study's primary outcome measure.
Price Action: SAGE stock is up 1.63% at $4.99 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/42089876/nokia-wins-multi-billion-dollar-deal-to-power-airtels-4g-and-5g-expansion-in-india" target="_blank" rel="noreferrer noopener">Nokia Wins Multi-Billion Dollar Deal To Power Airtel&#8217;s 4G And 5G Expansion In India</a></li>
</ul>

Biotech

Equities

Health Care

Movers

Trading Ideas

General

SAGE

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

SDOT

Sadot Group shares are trading higher. The CEO and CIO disclosed they purchased shares in the company through Form 4 filings.

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories A Build Of 2.054M Barrels Vs A Draw Of 4.407M Barrels Prior

QUBT

Quantum Computing shares are trading higher after the company announced it received a second order for its TFLN photonic chip foundry from the University of Texas.

USA EIA Weekly Distillates Stocks A Draw Of 0.114M Barrels Vs A Draw Of 1.394M Barrels Prior

Macro Notification

USA Crude Oil Inventories A Build Of 0.545M Barrels Vs  A Build Of 2.089M Barrels Prior

TransUnion's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) short percent of float has fallen 5.88% since its last report. The company recently reported that it has 4.35 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransUnion Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732116623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransUnion has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing TransUnion's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransUnion's peer group average for short interest as a percentage of float is 2.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(TRU) - Analyzing TransUnion's Short Interest

Kenvue's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) short percent of float has risen 23.31% since its last report. The company recently reported that it has 38.50 million shares sold short, which is 2.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kenvue Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732116617_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kenvue has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kenvue's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kenvue's peer group average for short interest as a percentage of float is 5.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

KVUE

How Is The Market Feeling About Kenvue?

Reinsurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) short percent of float has fallen 8.06% since its last report. The company recently reported that it has 288 thousand shares sold short, which is 0.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Reinsurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732116612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Reinsurance Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Reinsurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Reinsurance Gr's peer group average for short interest as a percentage of float is 1.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Reinsurance Gr's Recent Short Interest

TD Cowen analyst Thomas Boyes maintains PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) with a Buy and raises the price target from $10 to $15.

TD Cowen Maintains Buy on PureCycle Technologies, Raises Price Target to $15

DRMA

Dermata Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

U.S. stocks were lower, with the Nasdaq Composite falling more than 200 points on Wednesday.
Shares of Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) rose sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/WSM/earnings">better-than-expected third-quarter financial results.</a>
The company reported third-quarter adjusted earnings per share of $1.96, beating the analyst consensus of $1.78. Quarterly sales declined by 2.9% year-over-year to $1.8 billion, beating the street view of $1.79 billion. Comparable brand revenue was down 2.9% year-over-year.
Also, the company approved a $1 billion stock repurchase authorization.
Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) shares gained 22.7% to $168.48 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares jumped 35.3% to $6.41. Palladyne AI and Red Cat expanded partnership for Teal Drones.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares surged 33.3% to $6.12. The company reported third-quarter earnings on Tuesday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) rose 18.3% to $7.39.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) gained 18.2% to $4.0701.</li>
<li>Wix.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) gained 14.5% to $210.79 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>ATRenew Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NASDAQ">RERE</a>) gained 13.8% to $2.8000 following third-quarter results.</li>
<li>Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares rose 10.5% to $47.24 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue outlook.</li>
<li>HUTCHMED (China) Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) gained 10.1% to $18.44. HUTCHMED announced the appointment of independent non-executive director and member of board committee.</li>
<li>Dolby Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) gained 9.9% to $77.96 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY25 EPS guidance above estimates.</li>
<li>Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) rose 9.2% to $52.69.</li>
<li>Azenta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) gained 9.2% to $44.68. Flex will replace Azenta in the S&amp;P MidCap 400, and Azenta will replace Envestnet in the S&amp;P SmallCap 600 effective prior to the opening of trading on Monday, Nov. 25.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) gained 6.6% to $11.82.</li>
<li>Flex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) gained 6.3% to $39.69.</li>
<li>Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose 5.2% to $160.02 after the company reported better-than-expected quarterly financial results. Also, multiple firms raised their respective price targets on the stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42086593/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Intraday Update

Markets

ALHC

AZTA

BRKR

FLEX

GLBE

KEYS

NOVA

RCAT

RERE

TKNO

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday

TD Cowen analyst John Kernan maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Buy and raises the price target from $21 to $23.

TD Cowen Maintains Buy on Amer Sports, Raises Price Target to $23

<a href="https://www.webull.com/">Webull</a>, a leading digital investment platform, today announced the expansion of its crypto futures offering with Coinbase Derivatives, LLC (Coinbase Derivatives), a futures exchange registered with the Commodity Futures Trading Commission (CFTC). Webull users in the U.S. will be able to trade futures contracts for Bitcoin (BTI), nano Bitcoin (BIT), Ethereum (ETI), and nano Ether (ET) directly on the Webull platform.
Webull launched futures and commodities trading in March 2024, which expands access and grants users the ability to further diversify their portfolios and manage risk more effectively. Webull will be bringing its advanced trading tools and Coinbase Derivatives' crypto futures offerings together for a seamless experience.

COIN

Webull Announces The Expansion Of Its Crypto Futures Offering With Coinbase Derivatives; Users In The U.S. Will Be Able To Trade Futures Contracts For Bitcoin (BTI), Nano Bitcoin (BIT), Ethereum (ETI), And Nano Ether (ET) Directly On The Webull Platform

Private equity billionaire Marc Rowan, who has emerged as a contender for the Treasury Secretary post, has openly admitted to being "out of my depth" when it comes to understanding cryptocurrency's role in the <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42053981/trump-sec-pick-speculation-sends-this-altcoin-soaring-past-bitcoin-and-ethereum-in-daily-gains">U.S. financial system</a>.
What Happened: In a recent <a href="https://conversationswithtyler.com/episodes/marc-rowan/">podcast </a>with economist Tyler Cowen, the CEO of Apollo Global Management reflected on the complexities of cryptocurrency within the financial sector. 
Rowan criticized the limited understanding of crypto among prominent figures, including potential policymakers.
He said, "Out of my depth. Absolutely no idea," when asked directly about crypto's future role in the U.S. financial system.
Rowan further highlighted the potential for stablecoins and on-ramps to streamline the financial system but dismissed the relevance of alternative currencies in a regulated environment. 
"I see every opportunity for [stablecoins] to reduce the cost, to reduce the friction of dealing with the financial system," Rowan said.
However, he added, "In a KYC-AML world, I don't see a value for an alternative currency."
While Rowan was candid about his own lack of involvement in crypto through Apollo, his remarks raised questions about Warsh's readiness to tackle the growing importance of digital assets as a key component of financial policy.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084945/coinbase-ceo-brian-armstrong-backs-doge-initiative-how-blockchain-could-transform-government-efficiency">Coinbase CEO Brian Armstrong Backs DOGE Initiative: How Blockchain Could Transform Government Efficiency</a>
Why It Matters: Prediction market Polymarket currently <a href="https://polymarket.com/event/who-will-trump-nominate-for-treasury-secretary">places</a> former Federal Reserve Governor Kevin Warsh as the leading candidate for the Treasury Secretary position, with a 50% chance.
Other contenders are hedge fund manager Scott Bessent (20%) and Rowan (20%). However, the volatile market reflects the participants&#8217; uncertainty, with Bessent&#8217;s and Rowan&#8217;s chances having traded above 50% in recent days.
Elon Musk also weighed in on the selection process, using his social media platform X to endorse Howard Lutnick, CEO of <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Cantor Fitzgerald, for the position. </a>
While Lutnick was recently picked to lead the Commerce Department, Musk's public endorsement added another layer of speculation and reshaped the dynamics of the Treasury Secretary race.
Reports indicate that infighting among camps supporting Bessent and Lutnick has frustrated Trump, prompting him to consider alternatives. 
Rowan's candidacy has reportedly gained momentum following Lutnick's commerce appointment, while Bessent remains a strong competitor despite internal disputes.
The Treasury Secretary's role in shaping policies around these technologies will be critical as the U.S. faces growing competition from countries advancing their own <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40837533/put-in-the-cbdc-russian-central-bank-targets-july-2025-for-widespread-digital-ruble-use">central bank digital currencies (CBDCs)</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42072663/bitcoin-etf-options-could-smooth-volatility-become-available-on-robinhood-soon-expert-says">Bitcoin ETF Options Could Smooth Volatility, Become Available On Robinhood Soon, Expert Says</a></li>
</ul>
Image: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Could Donald Trump's Potential Treasury Secretary Be 'Out Of His Depth' On Crypto Policy? Polymarket Traders Just Can't Decide On A Favorite

TD Cowen analyst Oliver Chen maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.

TD Cowen Maintains Buy on Walmart, Raises Price Target to $100

Endeavour Silver shares are trading lower. The company entered into an agreement to sell 15,825,000 units of common stock to a syndicate of underwriters led by BMO Capital for gross proceeds of approximately $73 million.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a p...

Chemomab's Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Roth MKM analyst Jason Wittes maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $9.00. The ...

Roth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today. Michael Okunewitch has given h...

Chemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy Rating

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics has announced that its shareholders approved a proposal to grant 126,848...

Chemomab Therapeutics Aligns Leadership Incentives with Shareholders

Chemomab Therapeutics (CMMB) announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis was presented at the...

Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024

CMMB

Press Releases

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Financing

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Earnings

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Comments

Chemomab Therapeutics

Noticias

Últimas noticias sobre Chemomab Therapeutics (NASDAQ:CMMB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL